This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	IL-15	<p>Patient studies suggest IL-15 could be useful for treating colorectal cancer. In a cohort of patients with colorectal cancer, carriers of an IL-15 deletion had lower IL-15 expression and showed lower levels of B and T cell proliferation in the tumor microenvironment than patients without the deletion. Carriers of the <i>IL-15</i> deletion also showed increased risk of tumor recurrence and decreased survival. Next steps include developing mouse models to evaluate the therapeutic use of IL-15 alone and in combination with checkpoint inhibitors.</p> <p>Altor BioScience Corp. has ALT-803, an IL-15-mutant agonist complexed to an Fc fusion protein of IL-15 receptor α-chain (IL-15RA), in Phase I testing to treat melanoma and preclinical development for other cancers.</p> <p>Cytune Pharma S.A.S. has CYP0150, a fusion protein of IL-15 and IL-15RA, in preclinical development for cancer.</p> <p>SciBX 7(16); doi:10.1038/scibx.2014.456 Published online April 24, 2014</p>	<p>Patent application filed covering gene signature for cancer prognosis and tumor classification that includes IL-15; available for licensing and partnering</p>	<p>Mlecnik, B. <i>et al. Sci. Transl. Med.</i>; published online March 19, 2014; doi:10.1126/scitranslmed.3007240 Contact: Jérôme Galon, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: jerome.galon@crc.jussieu.fr</p>